BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37985547)

  • 1. SRSF7 is a promising prognostic biomarker in hepatocellular carcinoma and is associated with immune infiltration.
    Shen W; Yuan L; Cheng F; Wu Z; Li X
    Genes Genomics; 2024 Jan; 46(1):49-64. PubMed ID: 37985547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
    Luo Y; Liu H; Fu H; Ding GS; Teng F
    Front Immunol; 2022; 13():974377. PubMed ID: 36458010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Prognostic Genes in the Tumor Microenvironment of Hepatocellular Carcinoma.
    Xiang S; Li J; Shen J; Zhao Y; Wu X; Li M; Yang X; Kaboli PJ; Du F; Zheng Y; Wen Q; Cho CH; Yi T; Xiao Z
    Front Immunol; 2021; 12():653836. PubMed ID: 33897701
    [No Abstract]   [Full Text] [Related]  

  • 4. LPCAT1 acts as an independent prognostic biomarker correlated with immune infiltration in hepatocellular carcinoma.
    Li L; Wang X; Ding Y; Hui N; Su B; Yang M
    Eur J Med Res; 2022 Oct; 27(1):216. PubMed ID: 36307879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PCNT is a prognostic biomarker correlated with tumor immune microenvironment in hepatocellular carcinoma and promotes tumor progression by inhibiting cell cycle arrest.
    Wang X; Yang J; Luo L; Li X; Zhang Y
    Aging (Albany NY); 2023 May; 15(10):4122-4143. PubMed ID: 37211383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
    Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
    World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma.
    Zhu J; Huang Q; Peng X; Luo C; Liu Z; Liu D; Yuan H; Yuan R; Cheng X
    Front Immunol; 2023; 14():1218661. PubMed ID: 37662906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CXCL2/10/12/14 are prognostic biomarkers and correlated with immune infiltration in hepatocellular carcinoma.
    Lin T; Zhang E; Mai PP; Zhang YZ; Chen X; Peng LS
    Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34085699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of prognostic alternative splicing events related to the immune microenvironment of hepatocellular carcinoma.
    Yu S; Cai L; Liu C; Gu R; Cai L; Zhuo L
    Mol Med; 2021 Apr; 27(1):36. PubMed ID: 33832428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Unfolded Protein Response-Related mRNA Signature Predicting the Survival and Therapeutic Effect of Hepatocellular Carcinoma.
    Su Z; Wang L; Chen X; Zhong X; Wang D; Wang J; Shao L; Chen G; Wu J
    Comb Chem High Throughput Screen; 2022; 25(12):2046-2058. PubMed ID: 35125080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensively prognostic and immunological analysis of VRK Serine/Threonine Kinase 1 in pan-cancer and identification in hepatocellular carcinoma.
    Chen D; Zhou W; Chen J; Wang J
    Aging (Albany NY); 2023 Dec; 15(24):15504-15524. PubMed ID: 38157278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TANK-Binding Kinase 1 (TBK1) Serves as a Potential Target for Hepatocellular Carcinoma by Enhancing Tumor Immune Infiltration.
    Jiang Y; Chen S; Li Q; Liang J; Lin W; Li J; Liu Z; Wen M; Cao M; Hong J
    Front Immunol; 2021; 12():612139. PubMed ID: 33679751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and immunoprofiling of key prognostic genes in the tumor microenvironment of hepatocellular carcinoma.
    Wang T; Chen B; Meng T; Liu Z; Wu W
    Bioengineered; 2021 Dec; 12(1):1555-1575. PubMed ID: 33955820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of LOXL3-associating immune infiltration landscape and prognostic value in hepatocellular carcinoma.
    Wang N; Zhou X; Tang F; Wang X; Zhu X
    Virchows Arch; 2021 Dec; 479(6):1153-1165. PubMed ID: 34448895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
    Gao S; Zhang L; Wang H
    Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of chromatin organization-related gene signature for hepatocellular carcinoma prognosis and predicting immunotherapy response.
    Chen J; Chen X; Li T; Wang L; Lin G
    Int Immunopharmacol; 2022 Aug; 109():108866. PubMed ID: 35691273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive analysis of KLF2 as a prognostic biomarker associated with fibrosis and immune infiltration in advanced hepatocellular carcinoma.
    Chen XQ; Ma J; Xu D; Xiang ZL
    BMC Bioinformatics; 2023 Jun; 24(1):270. PubMed ID: 37386390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive Analysis of HHLA2 as a Prognostic Biomarker and Its Association With Immune Infiltrates in Hepatocellular Carcinoma.
    Ding L; Yu Q; Yang S; Yang WJ; Liu T; Xian JR; Tian TT; Li T; Chen W; Wang BL; Pan BS; Zhou J; Fan J; Yang XR; Guo W
    Front Immunol; 2022; 13():831101. PubMed ID: 35371079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long noncoding RNA PICSAR/miR-588/EIF6 axis regulates tumorigenesis of hepatocellular carcinoma by activating PI3K/AKT/mTOR signaling pathway.
    Liu Z; Mo H; Sun L; Wang L; Chen T; Yao B; Liu R; Niu Y; Tu K; Xu Q; Yang N
    Cancer Sci; 2020 Nov; 111(11):4118-4128. PubMed ID: 32860321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.
    Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM
    Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.